Evaluation of the AdvanDx VRE EVIGENE assay for detection of vanA in vancomycin-resistant Staphylococcus aureus.
AdvanDx VRE EVIGENE, a commercial vanA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated for the detection of vanA in Staphylococcus aureus. Performance was assessed using S. aureus, VRE, and vancomycin-intermediate and -susceptible isolates. The assay demonstrated 100% sensitivity and specificity when analyzed visually and by optical density.
Fosheim
G E
GE
Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, MS C16, 1600 Clifton Rd., Atlanta, GA 30333, USA.
Carey
R B
RB
Limbago
B M
BM
D001426:Bacterial Proteins / Q000032:analysis* / Q000235:genetics*; D019729:Carbon-Oxygen Ligases / Q000032:analysis* / Q000235:genetics*; D004269:DNA, Bacterial; D008826:Microbial Sensitivity Tests; D009693:Nucleic Acid Hybridization / Q000379:methods*; D012680:Sensitivity and Specificity; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics*; D020713:Vancomycin Resistance
D001426:Bacterial Proteins; D004269:DNA, Bacterial; C071437:VanA ligase, Bacteria; D019729:Carbon-Oxygen Ligases